- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Trametinib Receives European Approval for B-Raf-mutant Metastatic Melanoma
GSK has received marketing authorization from the European Commission for trametinib as monotherapy for unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
BRAF V600
The European Commission has given marketing authorization for trametinib as monotherapy for unresectable or metastatic melanoma in adults with a mutation, GlaxoSmithKline announced.
MEK1
MEK2
BRAF
BRAF V600
Trametinib (Mekinist), a kinase inhibitor that targets / activation and kinase activity, has not demonstrated clinical activity in patients who have progressed on a prior inhibitor therapy. Before taking trametinib, patients must have confirmation of a mutation using a validated test.
BRAF
V600E
V600K
The European Commission’s decision was based on results from the randomized, open-label phase 3 METRIC study of 322 patients with -mutant melanoma (types and ) who were either treatment-naïve or have received one prior chemotherapy treatment in the metastatic setting.
P
According to study results, treatment with trametinib resulted in a statistically significant increase in PFS compared to chemotherapy (HR= 0.45; 95% CI: 0.33, 0.63, <0.0001), with a median PFS of 4.8 months for patients taking trametinib (95% CI: 4.3, 4.9) vs. 1.5 months for chemotherapy (95% CI: 1.4, 2.7).
Read the original report: http://bit.ly/1rEVeHA
Source: Healio
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
